Rami Doukky to Risk
This is a "connection" page, showing publications Rami Doukky has written about Risk.
Connection Strength
0.290
-
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. J Nucl Cardiol. 2018 02; 25(1):137-149.
Score: 0.139
-
Age and gender as predictors of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: a substudy of the ASSUAGE trial. Am J Ther. 2013 Nov-Dec; 20(6):622-9.
Score: 0.108
-
Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. Am Heart J. 2020 12; 230:71-81.
Score: 0.043